Suchergebnisse - "Emadi, Ashkan"

PubPharm (134)

51

A Prospective Study of Peritransplant Sorafenib for Patients with FLT3-ITD Acute Myeloid Leukemia Undergoing Allogeneic Transplantation

enthalten in: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation | 2020

von Pratz, K. | Rudek, M. | Smith, B. | +14

52

Comparison of High-Dose Cytarabine, Mitoxantrone, and Pegaspargase (HAM-pegA) to High-Dose Cytarabine, Mitoxantrone, Cladribine, and Filgrastim (CLAG-M) as First-Line Salvage Cytotoxic Chemotherapy for Relapsed/Refractory Acute Myeloid Leukemia

enthalten in: Journal of clinical medicine | 2020

von Patzke, C. | Duffy, A. | Duong, V. | +5

53

High dose cytarabine, mitoxantrone, pegasapargase (HAM-pegA) in combination with dasatinib for the first-line treatment of Philadelphia chromosome positive mixed phenotype acute leukemia

enthalten in: American journal of leukemia research | 2020

von Patzke, C. | Emadi, A.

54

Optimizing pegylated asparaginase use : An institutional guideline for dosing, monitoring, and management

enthalten in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners | 2020

von Bade, N. | Lu, C. | Patzke, C. | +9

55

Peripheral blood blast rate of clearance is an independent predictor of clinical response and outcomes in acute myeloid leukaemia

enthalten in: British Journal of Haematology | 2020

von Holtzman, N. | El Chaer, F. | Baer, M. | +9

56

Characteristics and outcomes of therapy-related myeloid neoplasms after treatment for multiple myeloma

enthalten in: Leukemia & lymphoma | 2019

von Duong, V. | Holtzman, N. | Koka, R. | +7

57

Analysis of the Mechanisms of Action of Naphthoquinone-Based Anti-Acute Myeloid Leukemia Chemotherapeutics

enthalten in: Molecules (Basel, Switzerland) | 2019

von Lee, M. | Lapidus, R. | Ferraris, D. | +1

58

Refractory postallogeneic stem cell transplant pure red cell aplasia in remission after treatment with daratumumab

enthalten in: American journal of hematology | 2019

von Bathini, S. | Holtzman, N. | Koka, R. | +13

59

Equipotent doses of daunorubicin and idarubicin for AML : a meta-analysis of clinical trials versus in vitro estimation

enthalten in: Cancer chemotherapy and pharmacology | 2019

von Adige, S. | Lapidus, R. | Carter-Cooper, B. | +8

60

Equipotent doses of daunorubicin and idarubicin for AML: a meta-analysis of clinical trials versus in vitro estimation

enthalten in: Cancer chemotherapy and pharmacology | 2019

von Adige, S. | Lapidus, R. | Carter-Cooper, B. | +8